The split, finalized after the collaboration termination announced in November 2024, leaves neither company with outstanding financial obligations. Ascendis now holds the licenses to develop, manufacture, and commercialize products previously tied to the partnership, including its long-acting semaglutide candidate. This shift allows the company to pivot toward a self-directed pipeline targeting both rare metabolic disorders and broader cardiovascular indications.

Beyond the strategic shift in R&D, the board of directors signaled confidence in the company’s capital position by greenlighting the $400 million share buyback. With the legal hurdles of the Novo Nordisk agreement cleared, Ascendis is moving to aggressively scale its proprietary platform in the competitive obesity and Type 2 diabetes markets.